We are live on ! Find out more
CNTB

Connect Biopharma Holdings
CNTB

25 hedge funds and large institutions have $16.4M invested in Connect Biopharma Holdings in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 12 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

26% more capital invested

Capital invested by funds: $13M → $16.4M (+$3.4M)

4.05% less ownership

Funds ownership: 27.18% → 23.14% (-4%)

14% less funds holding

Funds holding: 29 → 25 (-4)

40% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 10

75% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 12

Holders
25
Holders Change
-4
Holders Change %
-13.79%
% of All Funds
0.43%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
3
Reduced
12
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
OCA
Octagon Capital Advisors
New York
+$541K
2
CL
CSS LLC
Illinois
+$22.5K
3
Renaissance Technologies
Renaissance Technologies
New York
+$19.7K
4
JP Morgan Chase
JP Morgan Chase
New York
+$3.39K
5
SA
SRH Advisors
Kansas
+$1.44K

Top Sellers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$637K
2
IC
Ikarian Capital
Texas
-$551K
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$481K
4
Citadel Advisors
Citadel Advisors
Florida
-$357K
5
DCM
DAFNA Capital Management
California
-$218K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$9.02M – – –
BlackRock
2
BlackRock
New York
$1.84M -$10.3K -8,532 -0.6%
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$1.65M -$481K -400,000 -24%
KCM
4
Kynam Capital Management
New Jersey
$954K – – –
UOC
5
UBS O'Connor
Illinois
$792K -$45.1K -37,575 -6%
SCM
6
Sio Capital Management
New York
$771K – – –
OCA
7
Octagon Capital Advisors
New York
$581K +$541K +450,000 New
IC
8
Ikarian Capital
Texas
$283K -$551K -458,358 -68%
Citigroup
9
Citigroup
New York
$277K -$193K -160,654 -43%
Renaissance Technologies
10
Renaissance Technologies
New York
$107K +$19.7K +16,400 +25%
CL
11
CSS LLC
Illinois
$50K +$22.5K +18,721 +94%
BFM
12
Boothbay Fund Management
New York
$35K -$61.3K -50,984 -65%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$24K – – –
TRCT
14
Tower Research Capital (TRC)
New York
$21K -$739 -615 -4%
Goldman Sachs
15
Goldman Sachs
New York
$17K -$7.16K -5,956 -31%
Morgan Stanley
16
Morgan Stanley
New York
$10K -$77 -64 -0.8%
JP Morgan Chase
17
JP Morgan Chase
New York
$4K +$3.39K +2,818 +1,118%
SA
18
SRH Advisors
Kansas
$2K +$1.44K +1,200 New
UBS Group
19
UBS Group
Switzerland
$1K -$126K -104,689 -100%
CUAMC
20
China Universal Asset Management Company
China
$1K +$477 +397 New
Simplex Trading
21
Simplex Trading
Illinois
$1K +$1.08K +903 New
BNP Paribas Financial Markets
22
BNP Paribas Financial Markets
France
$333 +$310 +258 New
Janus Henderson Group
23
Janus Henderson Group
United Kingdom
– -$637K -720,000 Closed
Citadel Advisors
24
Citadel Advisors
Florida
– -$357K -409,659 Closed
DCM
25
DAFNA Capital Management
California
– -$218K -250,000 Closed
1
2

CNTB Hedge Fund Activity: Q3 2022 in Review

25 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Connect Biopharma Holdings (CNTB) for Q3 2022, worth a combined $16.4M — up 26% from $13M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of CNTB and 6 opened new positions — a net loss of 4 holders — while 12 trimmed existing stakes and 3 added.

The largest buyer was Octagon Capital Advisors, opening a new position worth an estimated $541K. The largest seller was Janus Henderson Group, exiting entirely with an estimated $637K sold.

  • 25 institutional investors held Connect Biopharma Holdings (CNTB) as of Q3 2022, down from 29 in Q2 2022.
  • Funds reported $16.4M of Connect Biopharma Holdings stock for Q3 2022, up 26% quarter-over-quarter.
  • 6 funds opened new Connect Biopharma Holdings positions in Q3 2022 and 10 closed out, a net change of -4 holders.
  • The largest Connect Biopharma Holdings buyer in Q3 2022 was Octagon Capital Advisors, an estimated $541K added.
  • The largest Connect Biopharma Holdings seller in Q3 2022 was Janus Henderson Group, an estimated $637K sold.

Based on aggregated 13F filings for Q3 2022.